CEF方案新辅助化疗对乳腺癌患者血浆基质金属蛋白酶-2,-9活性的影响

Effect of CEF regimen neoadjuvant chemotherapy on activity levels of matrix metalloproteinase-2,-9 (MMP-2,-9) in breast cancer plasmas

目的探讨CEF联合化疗方案的新辅助化疗对乳腺癌患者血浆MMP-2,MMP-9的影响。方法利用光密度酶谱方法测定乳腺癌患者新辅助化疗期间血浆MMP-2,MMP-9活性水平。结果新辅助化疗第3个周期后血浆MMP-2,MMP-9活性水平均显著降低(P<0.01),化疗后部分缓解病例血浆MMP-2,MMP-9活性低于无效病例(P<0.01)。结论CEF方案新辅助化疗可能抑制乳腺癌患者血浆MMP-2,MMP-9活性,并且这两种酶的活性的变化可作为判定新辅助化疗疗效的指标。

[Objective] To investigate the putative effects of the activity levels of MMP-2,-9 in the plasmas of breast cancer. [Methods] The values of MMP-9 and MMP-2 in breast cancer plasmas were determined by densitometrie scan of zymograms during the period of neoadjuvant chemotherapy. [Results] The expression levels of MMP-2 andMMP-9 in breast cancer patients were both signifieiantly decreased after the third period of neoadjuvant chemotherapy （P 〈0.01）. And the levels of the enzymes were both significantly lower in PR than in NR （P 〈0.01）. [Conclusion] The CEF regimen neoadjuvant chemotherapy may inhibit the activity of matrix metalloproteinase-2,- 9 in breast cancer plasmas,and the changes of the activity of the two enzymes may serve as predictors of clinical response to neoadiuvant chemotherapy.